10.22.26 -- From Psychedelics To Rare Disease: Navigating Regulatory Hurdles

Psychedelic trials demand rare expertise. See how the right team tackles regulatory hurdles, site readiness, and protocol design to keep your study moving forward.

Move drug development into the modern era with a CRO that offers assay development and validation, bioanalytical testing, sample prep, and more.

Global clinical trials need central laboratory networks able to scale across countries while keeping biomarker and biospecimen data consistent from one study site to the next.

Learn how wearables and DHTs are alleviating the trial participation burden, increasing the likelihood of trial success, and enhancing the overall management of these conditions.

The next era of clinical trials will be defined by global expansion across the Asia-Pacific region, rapid and cost-effective pathways to regulatory approval, and reliable, patient-centric leadership.

Oversight in 2026 requires adaptability as AI, consent standards, and regulatory uncertainty challenge sponsors and IRBs to balance ethics with innovation through proactive planning and collaboration.

One platform, multiple payloads: how delivery systems can lower costs and boost access. Parexel experts break down the regulatory data that matters on Cell & Gene Unscripted.

Navigate key considerations for psychedelic clinical development, from FDA recommendations and abuse potential evaluation to blinding and early-phase trial design.

AI in clinical research poses governance challenges. Clear ownership, consistent policies, and aligned teams help manage risk, ensure compliance, and drive responsible innovation in complex trials.

As one of the world’s largest and most experienced safety and PV organizations, unearth how this provider is bringing extensive expertise and regulatory intelligence to every industry engagement.